Effects of pioglitazone on lipid and lipoprotein metabolism. - Wikidata - wikimedia - TriplyDB

Effects of pioglitazone on lipid and lipoprotein metabolism.

Effects of pioglitazone on lipid and lipoprotein metabolism.

http://www.wikidata.org/entity/Q36909527

about

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline Acute Effect of Metformin on Postprandial Hypertriglyceridemia through Delayed Gastric Emptying Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis Glitazones for human nonalcoholic steatohepatitis The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes.Comparative Effect of Insulin Sensitizers and Statin on Metabolic Profile and Ultrasonographical Score in Non Alcoholic Fatty Liver Disease.Thiazolidinediones as therapy for endometriosis: a case series.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Lipid effects of endocrine medications.The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.Pharmacological agents for NASH.Intestinal nuclear receptors in HDL cholesterol metabolism.Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells.Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.Long-Term Effect of Alogliptin on Glycemic Control in Japanese Patients With Type 2 Diabetes: A 3.5-Year Observational Study.Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients.Pathophysiology of Diabetic Dyslipidemia Thiazolidinedione induces a therapeutic effect on hepatosteatosis by regulating stearoyl-CoA desaturase-1, lipase activity, leptin and resistin

P2860

Q24608464-D876B2C0-9957-4BA9-8238-0492E9D32EBC Q33839003-D2D60321-F49C-447A-8B4F-C5A9569867F0 Q33880174-D1C5757B-9097-4F0A-955C-4F2E69EE794D Q35191067-F1901983-E123-43DB-A372-3311FE061CFE Q36969616-E25EB732-6F8E-48CD-81E3-52943C141ADB Q37266575-1EBD16CD-A0BC-4296-8381-756ECF183ED3 Q37466788-75C55442-3977-4DB7-BFD4-AAF2DA81FB61 Q37577162-53856074-2F34-4143-A77C-AAA668CA38E5 Q37811982-92072B5E-9035-49DA-83BF-48AA978A1053 Q38102596-ACB21513-DD48-46F8-BE1E-C31451D7FAF0 Q38152646-A58E0257-08EF-4BFA-9608-05CF59B22805 Q38234847-31550166-74E0-40BC-B0A0-485B27CDE57A Q38921141-69CE4442-16E0-4FDF-8A5B-8ACB2053F80A Q38974109-A5EFC3BB-35DD-408B-AC44-125A3E77ACAB Q39320400-5F6285EC-2866-4790-BAC5-0DDFF8BBA37E Q41258262-B8087A71-631C-4FF0-93F4-AF62AEAB3449 Q46024732-3A74D78F-4524-49AB-917E-9FF67DD973C4 Q58774678-40EF39CD-91CE-4B23-A206-356EAED8BA8A Q58802792-2D565745-DBE3-4BB9-B29B-197C42F8C0C7

P2860

Effects of pioglitazone on lipid and lipoprotein metabolism.

http://www.wikidata.org/entity/Q36909527

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Effects of pioglitazone on lipid and lipoprotein metabolism.

@en

type

label

Effects of pioglitazone on lipid and lipoprotein metabolism.

@en

prefLabel

Effects of pioglitazone on lipid and lipoprotein metabolism.

@en

P1433

Q36909527-401B531F-9F18-4A00-8CA7-13401D6255A5

P1476

Q36909527-46A24E37-E1F4-42EE-95CA-D68155377A47

P2093

Q36909527-81152871-2766-4E24-A00E-88F8CDA22627

P2860

Q36909527-0617B5F2-C723-49FF-ADE0-4C5D27C42827

Q36909527-09273210-D11B-4E54-A676-B35576038B6E

Q36909527-1CB1CC1D-72C3-447B-984B-DC28EFF2F60F

Q36909527-36827A9C-C630-4702-B28B-B327EDAC442C

Q36909527-39085AFA-CBA0-4041-B2AB-6D29281850CB

Q36909527-3D110156-A325-43CE-BF29-8087D8072DCC

Q36909527-3EBB7F62-BFC7-4DA0-A1A8-91AE2C6B7D14

Q36909527-3F67E5A7-3FAC-4350-8684-B211BEDEAC4B

Q36909527-40FCF139-3D48-404D-A4A1-B6CA44F63F94

Q36909527-4665A0A2-B008-4E49-A02E-C82914901718

P304

Q36909527-E6A62666-CD05-47AE-851B-3681F75E8005

P31

Q36909527-3198539B-AC9C-40BC-A236-1C58920BB73D

P356

Q36909527-A465D357-33DB-47D4-AFDB-5726E92579DA

P433

Q36909527-64D1FB67-372A-4A96-9EE8-F3447149B9BD

P478

Q36909527-F17A8C86-2484-42EE-B5C3-2C47E3BDEBBC

P577

Q36909527-01DCC894-2D5D-4B15-90B8-12EB8B568B30

P698

Q36909527-D1C1275C-F3A0-475D-A772-148DE4EF98AA

P356

J.1463-1326.2007.00715.X

P1433

Diabetes, Obesity and Metabolism

P1476

Effects of pioglitazone on lipid and lipoprotein metabolism.

@en

P2093

D John Betteridge

http://www.w3.org/2001/XMLSchema#string

P2860

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

New insight into the pathophysiology of lipid abnormalities in type 2 diabetes.

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

P304

640-647

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1463-1326.2007.00715.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17697057

http://www.w3.org/2001/XMLSchema#string